Tetrahydrocurcumin
A colourless metabolite of curcumin, produced in the gut and sold as a supposedly more bioavailable and more antioxidant alternative. Human evidence amounts to one tiny pilot trial.
Evidence last reviewed: August 2026
What the science says
- Depression as an add-on Limited evidence
A randomised open-label pilot trial in 19 patients with major depressive disorder compared escitalopram alone with escitalopram plus 200 mg/day tetrahydrocurcumin. With 19 participants and no blinding of treatment, this is a preliminary signal rather than a result.
- Metabolic and antioxidant effects Limited evidence
Reviews of curcumin metabolites describe effects on glucose and lipid regulation and stronger antioxidant activity than curcumin itself in laboratory assays. Essentially all of this work is in cells and rodents.
- Bioavailability advantage Limited evidence
The claim that supplemental tetrahydrocurcumin achieves better exposure than curcumin has not been demonstrated in a head-to-head human pharmacokinetic trial. Most published bioavailability comparisons involve formulated curcumin products, not tetrahydrocurcumin.
Dosage & safety
Scientific references
Where to buy
Referral link — this site may earn a commission on purchases.
Related in Longevity & antioxidants
- Beta-Carotene Limited evidence
- Vitamin E Limited evidence
- Astaxanthin Limited evidence
- Chaga Mushroom Limited evidence
- Olive Fruit Extract (Hydroxytyrosol) Limited evidence
- PQQ Limited evidence